← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicGileadgovitecan-hziy (Trodelvy), …Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan-hziy)

Metastatic Urothelial Cancer · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 34.3%임상시험 42상태 RECRUITING
ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 19%임상시험 41상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 41상태 RECRUITING
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…deruxtecan have preventive …Phase 2

Brigatinib (Brigatinib)

Breast Cancer; Gastrointestinal Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 74.5%임상시험 40상태 ACTIVE
ADCBiologicAstraZenecaderuxtecan (Dato-DXd, Datro…Phase 3

Dato-DXd (Dato-DXd)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 79%임상시험 40상태 RECRUITING
CGTBiologicOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 89%임상시험 40상태 RECRUITING
CGTBiologicViroMissile, Inc.foreignPhase 1

oncolytic vaccinia virus (IDOV-Immune, IDOV-Immune (oncolytic vaccinia virus))

Colorectal Cancer; Pancreatic Cancer · Colorectal Cancer

#ColorectalCancer#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80%임상시험 40상태 RECRUITING
AntibodyRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+5
임상시험 39상태 RECRUITING
ADCBiologicMirati Therapeutics Inc.biodistributionPhase 3

Adagrasib (Adagrasib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Dynamic Tumor Resistance

#DynamicTumorResistance#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 31.9%임상시험 38상태 RECRUITING
AntibodyGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 38상태 RECRUITING
ADCBiologicNYU Langone Healthderuxtecan (T-DXd) (PFS HR&…Phase 2

Elacestrant (Elacestrant)

ER Positive, HER2 Positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 38상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Selpercatinib (Selpercatinib)

Breast Cancer; Gastrointestinal Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 100%임상시험 38상태 ACTIVE
AntibodyGlaxoSmithKlinesPhase 3

Tarlatamab (Tarlatamab)

Neoplasms · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+4
효능 ORR 57.1%임상시험 36상태 RECRUITING
ADCBiologicBeijing Biostar Pharmaceuticals…Phase 2

Utidelone (Utidelone)

Non-small Cell Lung Cancer Patients with Brain Metastases · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 36상태 RECRUITING
AntibodyHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 81.3%임상시험 35상태 ACTIVE
CGTBiologicOncolytics BiotechPhase 2

Pelareorep (Pelareorep)

Breast Cancer Metastatic · Breast Cancer Metastatic

#BreastCancerMetastatic#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 27%임상시험 35상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING
ADCBiologicAkesoaxisPhase 3

Platinum chemotherapy (Platinum chemotherapy)

Advanced Non Small Cell Lung Cancer (NSCLC) · Advanced Non Small Cell Lung Cancer (NSC

#AdvancedNonSmallCellLungCancerNS#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 65.1%임상시험 32상태 RECRUITING
AntibodyETOP IBCSG Partners Foundationderuxtecan (Arm 4), followe…Phase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 45%임상시험 31상태 RECRUITING

11 / 75 페이지

← 이전다음 →